The effect of statin treatment on mitochondrial function and lipid oxidation

Is mitochondrial function and lipid oxidation impaired in patients treated with simvastatin compared with well matched controls?

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN97637728

Enrollment

Registered

2018-03-21

Start date

2010-01-01

Completion date

Unknown

Last updated

2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mitochondrial function and lipid oxidation Nutritional, Metabolic, Endocrine Mitochondrial function and lipid oxidation

Interventions

The study is a cross-sectional study, so there was no intervention. 10 healthy volunteers are recruited, and 10 participants taking simvastatin. Participants are matched for age, activity level, maxim

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Simvastin group 1. Male participants aged 30-60 years 2. Normal kidney and liver function 3. BMI between 25-35 4. Taking simvastatin for at least 1 year 5. Does not have type II Diabetes Control group 1. Male participants aged 30-60 years 2. Normal kidney and liver function 3. BMI between 25-35 4. Does not have type II Diabetes

Exclusion criteria

Exclusion criteria: 1. Must not be taking medication (other than simvastatin). 2. Must not be disposed to type 2 diabetes

Design outcomes

Primary

Measure	Time frame
Mitochondrial function measured by high-resolution respirometry and lipid oxidation (whole body lipid oxidation) and protein analysis at the second visit.	—

Secondary

Measure	Time frame
Glucose homeostasis measured using the oral glucose tolerance test at the first visit.	—

Countries

Denmark

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026